Quick access to main page (top) Direct access to main contents Quick access to main page (bottom)

Why Europe’s Military Experts Are Buzzing About Korea’s KF-21 Boramae

inews24 Views  

South Korea’s supersonic fighter jet, the KF-21 Boramae, recently entered mass production, drawing attention from the global defense industry, including Asia and Europe. One key factor in this attention is its competitive pricing.

During the opening ceremony of Seoul ADEX 2023 held at Seoul Airport in Seongnam, Gyeonggi Province, on October 17th last year, the domestically produced 4.5th-generation KF-21 Boramae was seen flying overhead. (Photo credit: Newsis)

According to industry sources yesterday, the French military magazine Meta Défense France highlighted the KF-21 Boramae, emphasizing its cost advantage. The publication noted, “The KF-21 has a price advantage over the Rafale and Typhoon while offering excellent performance thanks to its proven technology and scalable development.” It also mentioned that the KF-21 is a candidate for Peru’s next-generation fighter program, alongside France’s Rafale, describing the KF-21 as an economical and industrial alternative to Russian aircraft.

The KF-21 Boramae is a supersonic fighter developed by South Korea through a collaboration between Korea Aerospace Industries (KAI) and the Agency for Defense Development (ADD). The first KF-21 to enter mass production last month is scheduled for delivery to the Air Force by late 2026, with 120 units to be deployed by 2032. KAI and the Air Force plan to deploy the initial Block-1 units, focusing on air-to-air combat capabilities, by 2028. Afterward, the Block-2 units, which will have additional air-to-ground and air-to-ship combat capabilities, will be successively deployed to enhance the jet’s multi-role capabilities.

The KF-21 incorporates stealth technology to reduce radar cross-sections and can perform air combat and ground attack missions. It also integrates cutting-edge technologies from the Fourth Industrial Revolution, including AI and big data. As a 4.5th-generation fighter, the KF-21 bridges the gap between 4th—and 5th-generation fighters.

KF-21 Boramae (Photo credit: Newsis)

The KF-21’s competitors include the Dassault Rafale, the Eurofighter Typhoon, and the F-16 and F-15EX. While the exact price of the KF-21 has not been disclosed, it is said to be 30 to 40% cheaper than these rival models. A KAI official stated, “Since we are just beginning mass production, it’s difficult to provide a definite figure, but overall, the price is expected to be competitive.”

The Philippines has also shown interest in the KF-21. The country sent a Request for Information (RFI) to KAI late last month, asking for technical and other critical details. A KAI official confirmed, “While it’s true that the Philippines is interested and considering the KF-21, it’s unlikely that a concrete decision will be made this year. We are still in the early stages of mass production, and details regarding the project’s scale or timeline have not been revealed. Currently, we are focusing on marketing and responding to inquiries.”

Meanwhile, KAI is working to further evolve the KF-21 Boramae into a next-generation air combat model suitable for future warfare. As part of the Next-generation Air Combat System (NACS) plan, the KF-21 will be equipped with a manned-unmanned collaborative data link and operate alongside multi-purpose unmanned aircraft (AAP).

inews24
content@viewusglobal.com

Comments0

300

Comments0

[WORLD] Latest Stories

  • Porsche Taycan GTS Breaks Guinness Record with 10.9-Mile Ice Drift
  • Africa's MPOX Variant Clade 1b Reaches France: Health Officials Take Action
  • LA Wildfires’ Economic Toll Hits $50 Billion, Doubling Early Estimates
  • Real Reason Trump Wants Greenland and the Panama Canal: Geopolitical Dominance
  • Biden Targets China, Russia with New Semiconductor Export Limits
  • Wildfire Chaos in California: 150,000 Evacuated as Flames Spread

You May Also Like

  • 1
    FDA Greenlights Sanofi's Qfitlia for Hemophilia—An Innovative Alternative to Daily Injections

    LIFESTYLE 

  • 2
    Prostate Cancer Screenings May Cut Death Risk in Half, Study Finds

    LIFESTYLE 

  • 3
    It’s Not Just Depression: Personality Disorders Linked to Highest Suicide Risk

    LIFESTYLE 

  • 4
    Faster Cancer Treatment? Merck Launch Set for Subcutaneous Keytruda Rollout

    LIFESTYLE 

  • 5
    Cutting Carbs? You Might Be Raising Your Risk of Colon Cancer

    LIFESTYLE 

Popular Now

  • 1
    Tired of the Buzz? Fruit and Dairy Might Help, New Study Says

    LIFESTYLE&nbsp

  • 2
    Study Finds Missing Gut Bacteria in Parkinson’s and IBD Patients

    LIFESTYLE&nbsp

  • 3
    New Research Reveals Ketogenic Diet Slows Biological Aging by 6+ Years

    LIFESTYLE&nbsp

  • 4
    New Drug Cuts Heart Disease Risk by 94%—And Has No Major Side Effects

    LIFESTYLE&nbsp

  • 5
    Wegovy Maker Strikes $1B Deal for Next-Gen Obesity Treatment

    LIFESTYLE&nbsp

Must-Reads

  • 1
    FDA Greenlights Sanofi's Qfitlia for Hemophilia—An Innovative Alternative to Daily Injections

    LIFESTYLE 

  • 2
    Prostate Cancer Screenings May Cut Death Risk in Half, Study Finds

    LIFESTYLE 

  • 3
    It’s Not Just Depression: Personality Disorders Linked to Highest Suicide Risk

    LIFESTYLE 

  • 4
    Faster Cancer Treatment? Merck Launch Set for Subcutaneous Keytruda Rollout

    LIFESTYLE 

  • 5
    Cutting Carbs? You Might Be Raising Your Risk of Colon Cancer

    LIFESTYLE 

Popular Now

  • 1
    Tired of the Buzz? Fruit and Dairy Might Help, New Study Says

    LIFESTYLE 

  • 2
    Study Finds Missing Gut Bacteria in Parkinson’s and IBD Patients

    LIFESTYLE 

  • 3
    New Research Reveals Ketogenic Diet Slows Biological Aging by 6+ Years

    LIFESTYLE 

  • 4
    New Drug Cuts Heart Disease Risk by 94%—And Has No Major Side Effects

    LIFESTYLE 

  • 5
    Wegovy Maker Strikes $1B Deal for Next-Gen Obesity Treatment

    LIFESTYLE